An­oth­er biotech grabs the axe, chop­ping R&D in a ma­jor re­or­ga­ni­za­tion as drug sales dis­ap­point

Heron Ther­a­peu­tics has been sore­ly test­ed in its tran­si­tion from an R&D com­pa­ny to a com­mer­cial­iza­tion fo­cus, los­ing 70% of its mar­ket cap $HRTX in Nas­daq’s storm-tossed wa­ters since the be­gin­ning of the year.

Now it’s time to shake things up in the in­ter­est of buy­ing it­self more time, join­ing the down­siz­ing move­ment in the midst of a bear mar­ket. And the axe is falling pri­mar­i­ly on R&D.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER